WO2019155151A3 - Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations - Google Patents

Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations Download PDF

Info

Publication number
WO2019155151A3
WO2019155151A3 PCT/FR2019/050245 FR2019050245W WO2019155151A3 WO 2019155151 A3 WO2019155151 A3 WO 2019155151A3 FR 2019050245 W FR2019050245 W FR 2019050245W WO 2019155151 A3 WO2019155151 A3 WO 2019155151A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor subtype
endothelin receptor
antibody against
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2019/050245
Other languages
English (en)
Other versions
WO2019155151A2 (fr
Inventor
Didier Boquet
Amaury HERBET
Frédéric Ducancel
Narciso COSTA
Jean-Yves Couraud
Jean-Philippe Hugnot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to EP19744751.9A priority Critical patent/EP3735428A2/fr
Priority to JP2020542857A priority patent/JP7456930B2/ja
Priority to US16/967,763 priority patent/US12084505B2/en
Publication of WO2019155151A2 publication Critical patent/WO2019155151A2/fr
Publication of WO2019155151A3 publication Critical patent/WO2019155151A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre le sous-type A des récepteurs aux endothélines notamment monoclonaux, un fragment ou un dérivé de ceux-ci. La présente invention concerne également l'utilisation thérapeutique, diagnostique ou comme outil de recherche d'un tel anticorps dans le domaine des cancers et notamment du glioblastome.
PCT/FR2019/050245 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations Ceased WO2019155151A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP19744751.9A EP3735428A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations
JP2020542857A JP7456930B2 (ja) 2018-02-07 2019-02-04 エンドセリン受容体サブタイプａに対する抗体及びその使用
US16/967,763 US12084505B2 (en) 2018-02-07 2019-02-04 Antibody against the endothelin receptor subtype A, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851026A FR3077574B1 (fr) 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
FR1851026 2018-02-07

Publications (2)

Publication Number Publication Date
WO2019155151A2 WO2019155151A2 (fr) 2019-08-15
WO2019155151A3 true WO2019155151A3 (fr) 2019-12-12

Family

ID=62017513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2019/050245 Ceased WO2019155151A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations

Country Status (5)

Country Link
US (1) US12084505B2 (fr)
EP (1) EP3735428A2 (fr)
JP (1) JP7456930B2 (fr)
FR (1) FR3077574B1 (fr)
WO (1) WO2019155151A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165823A2 (fr) * 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095353A2 (fr) * 2006-02-14 2007-08-23 Geisinger Clinic Récepteurs gpcr utilisés comme cibles pour l'angiogenèse
CN103728454A (zh) * 2012-10-10 2014-04-16 上海博戍生物科技有限公司 基于表位抗原肽的抗内皮素受体a抗体酶联免疫检测方法及其在ctd-pah中的应用
CA2971491A1 (fr) * 2014-12-05 2017-06-08 Gmax Biopharm Llc. Anticorps de liaison au recepteur de l'endotheline humaine et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2008280266A (ja) 2007-05-09 2008-11-20 Sekisui Chem Co Ltd モノクローナル抗体
FR2965810B1 (fr) 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
FR3053042B1 (fr) 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095353A2 (fr) * 2006-02-14 2007-08-23 Geisinger Clinic Récepteurs gpcr utilisés comme cibles pour l'angiogenèse
CN103728454A (zh) * 2012-10-10 2014-04-16 上海博戍生物科技有限公司 基于表位抗原肽的抗内皮素受体a抗体酶联免疫检测方法及其在ctd-pah中的应用
CA2971491A1 (fr) * 2014-12-05 2017-06-08 Gmax Biopharm Llc. Anticorps de liaison au recepteur de l'endotheline humaine et leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. HERBET ET AL: "Antibodies Targeting Human Endothelin-1 Receptors Reveal Different Conformational States in Cancer Cells", PHYSIOLOGICAL RESEARCH., 6 May 2018 (2018-05-06), CZ, pages S257 - S264, XP055635431, ISSN: 0862-8408, DOI: 10.33549/physiolres.933848 *
IRANI SOUSSAN ET AL: "A review of the profile of endothelin axis in cancer and its management", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 89, no. 2, 4 September 2013 (2013-09-04), pages 314 - 321, XP028817538, ISSN: 1040-8428, DOI: 10.1016/J.CRITREVONC.2013.08.011 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *

Also Published As

Publication number Publication date
JP7456930B2 (ja) 2024-03-27
FR3077574A1 (fr) 2019-08-09
FR3077574B1 (fr) 2022-04-01
WO2019155151A2 (fr) 2019-08-15
US20220089755A1 (en) 2022-03-24
US12084505B2 (en) 2024-09-10
JP2021513345A (ja) 2021-05-27
EP3735428A2 (fr) 2020-11-11

Similar Documents

Publication Publication Date Title
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
WO2020121195A8 (fr) Anticorps trem2 et leurs utilisations
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
AU2015347015A8 (en) Antibody drug conjugates
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018008592A (es) Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
CA2886433C (fr) Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017004026A8 (fr) Anticorps anti-cd 123 et conjugués et dérivés correspondants
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
GEAP202014437A (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
NZ604003A (en) Monoclonal antibodies against her2
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
EP3705494A3 (fr) Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
MA39896A (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
ZA202008095B (en) Humanized antibodies against psma

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020542857

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019744751

Country of ref document: EP

Effective date: 20200806

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19744751

Country of ref document: EP

Kind code of ref document: A2